GlassScriptPhysician profile
Thomas A Showalter
NPI 1780853358
$810.27
in general payments reported to CMS, 2019-2025
12 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.17 · 2020: $35.65 · 2022: $134 · 2023: $48.93 · 2024: $108 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.12 |
| Education | $101.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.66 | 2019-2025 | |
| Galvanize Therapeutics, INC | $176.58 | 2025 | Aliya System |
| Sirtex Medical INC | $134.13 | 2022 | |
| Pfizer INC. | $53.34 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $47.86 | 2023-2024 | Orgovyx |
| Abbvie INC. | $41.53 | 2025 | |
| Merck Sharp & Dohme LLC | $21.13 | 2025 | Keytruda Qlex, Keytruda |
| Stemline Therapeutics INC. | $20.81 | 2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $20.67 | 2019 | |
| Genentech USA, INC. | $19.81 | 2025 | Polivy |
| Alexion Pharmaceuticals, INC. | $19.61 | 2025 | Ultomiris |
| Astellas Pharma US INC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Showalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.